Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Principal Financial Group Inc.

Principal Financial Group Inc. trimmed its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 16.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 376,195 shares of the biopharmaceutical company’s stock after selling 71,892 shares during the period. Principal Financial Group Inc.’s holdings in Halozyme Therapeutics were worth $17,986,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of HALO. State of New Jersey Common Pension Fund D lifted its stake in Halozyme Therapeutics by 0.6% during the fourth quarter. State of New Jersey Common Pension Fund D now owns 47,663 shares of the biopharmaceutical company’s stock valued at $2,279,000 after buying an additional 302 shares in the last quarter. Sheaff Brock Investment Advisors LLC raised its holdings in shares of Halozyme Therapeutics by 8.8% during the fourth quarter. Sheaff Brock Investment Advisors LLC now owns 7,747 shares of the biopharmaceutical company’s stock valued at $370,000 after acquiring an additional 629 shares during the period. Nations Financial Group Inc. IA ADV lifted its position in shares of Halozyme Therapeutics by 2.4% in the 4th quarter. Nations Financial Group Inc. IA ADV now owns 14,062 shares of the biopharmaceutical company’s stock valued at $672,000 after acquiring an additional 328 shares in the last quarter. Rhumbline Advisers boosted its stake in Halozyme Therapeutics by 1.4% in the 4th quarter. Rhumbline Advisers now owns 410,508 shares of the biopharmaceutical company’s stock worth $19,626,000 after purchasing an additional 5,833 shares during the period. Finally, Vontobel Holding Ltd. acquired a new position in Halozyme Therapeutics in the 4th quarter worth approximately $377,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Price Performance

Shares of HALO opened at $58.50 on Tuesday. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80. The firm has a market cap of $7.20 billion, a PE ratio of 17.06, a PEG ratio of 0.42 and a beta of 1.25. The firm’s 50 day moving average price is $53.67 and its 200 day moving average price is $54.67. Halozyme Therapeutics, Inc. has a twelve month low of $37.73 and a twelve month high of $65.53.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, beating analysts’ consensus estimates of $1.17 by $0.02. The business had revenue of $298.01 million for the quarter, compared to the consensus estimate of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. As a group, research analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on HALO shares. HC Wainwright increased their target price on Halozyme Therapeutics from $70.00 to $72.00 and gave the company a “buy” rating in a report on Wednesday, February 19th. Wells Fargo & Company dropped their price target on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Benchmark restated a “buy” rating and set a $75.00 price objective on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. JMP Securities upped their target price on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a report on Friday, November 1st. Finally, Piper Sandler increased their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research report on Friday, January 10th. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $62.78.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 5,000 shares of the stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $56.30, for a total transaction of $281,500.00. Following the transaction, the director now owns 38,611 shares in the company, valued at $2,173,799.30. This trade represents a 11.46 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.